Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
IRVINE, Calif., Aug. 24, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Avinger shares on or about the IPO, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Avinger filed documents in connection with the IPO that contained materially false and misleading statements and/or failed to disclose: that Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; that Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result, the Company was experiencing lower sales and revenues. When this information was released, Avinger’s share price dropped, causing investors harm according to the Complaint. On May 3, 2017, the stock closed at $0.57 per share, a decline of over 95% from the IPO price.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
